These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33724128)

  • 1. Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy.
    Lattanzi S; Riva A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1317-1332. PubMed ID: 33724128
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurosteroids as Novel Anticonvulsants for Refractory Status Epilepticus and Medical Countermeasures for Nerve Agents: A 15-Year Journey to Bring Ganaxolone from Bench to Clinic.
    Reddy DS
    J Pharmacol Exp Ther; 2024 Jan; 388(2):273-300. PubMed ID: 37977814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.
    Chuang SH; Reddy DS
    J Pharmacol Exp Ther; 2020 Mar; 372(3):285-298. PubMed ID: 31843812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus.
    Zolkowska D; Wu CY; Rogawski MA
    Epilepsia; 2018 Oct; 59 Suppl 2(Suppl 2):220-227. PubMed ID: 29453777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganaxolone.
    Nohria V; Giller E
    Neurotherapeutics; 2007 Jan; 4(1):102-5. PubMed ID: 17199022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrasynaptic γ-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures.
    Reddy DS; Carver CM; Clossen B; Wu X
    Epilepsia; 2019 Apr; 60(4):730-743. PubMed ID: 30895610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithium-Pilocarpine-Induced Status Epilepticus in Rats: Comparison with Allopregnanolone.
    Saporito MS; Gruner JA; DiCamillo A; Hinchliffe R; Barker-Haliski M; White HS
    J Pharmacol Exp Ther; 2019 Mar; 368(3):326-337. PubMed ID: 30552296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy.
    Reddy DS; Rogawski MA
    J Pharmacol Exp Ther; 2000 Sep; 294(3):909-15. PubMed ID: 10945840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurosteroid replacement therapy for catamenial epilepsy.
    Reddy DS; Rogawski MA
    Neurotherapeutics; 2009 Apr; 6(2):392-401. PubMed ID: 19332335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ganaxolone on flurothyl seizures in developing rats.
    Liptáková S; Velísek L; Velísková J; Moshé SL
    Epilepsia; 2000 Jul; 41(7):788-93. PubMed ID: 10897148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of catamenial epilepsy.
    Reddy DS
    Methods Find Exp Clin Pharmacol; 2004 Sep; 26(7):547-61. PubMed ID: 15538544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganaxolone: First Approval.
    Lamb YN
    Drugs; 2022 Jun; 82(8):933-940. PubMed ID: 35596878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.
    Gould A; Amin S
    Expert Rev Neurother; 2024 Oct; 24(10):945-951. PubMed ID: 39082513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.
    Vaitkevicius H; Ramsay RE; Swisher CB; Husain AM; Aimetti A; Gasior M
    Epilepsia; 2022 Sep; 63(9):2381-2391. PubMed ID: 35748707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric super-refractory status epilepticus treated with allopregnanolone.
    Broomall E; Natale JE; Grimason M; Goldstein J; Smith CM; Chang C; Kanes S; Rogawski MA; Wainwright MS
    Ann Neurol; 2014 Dec; 76(6):911-5. PubMed ID: 25363147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience.
    Singh RK; Singh R; Stewart A; Van Poppel K; Klinger S; Hulihan J; Van Heusen H; Vaitkevicius H; Gasior M
    Epilepsy Behav Rep; 2022; 20():100567. PubMed ID: 36325100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroactive steroids for the treatment of status epilepticus.
    Rogawski MA; Loya CM; Reddy K; Zolkowska D; Lossin C
    Epilepsia; 2013 Sep; 54 Suppl 6(0 6):93-8. PubMed ID: 24001085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurosteroids and Seizure Activity.
    Miziak B; Chrościńska-Krawczyk M; Czuczwar SJ
    Front Endocrinol (Lausanne); 2020; 11():541802. PubMed ID: 33117274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-apoptotic Actions of Allopregnanolone and Ganaxolone Mediated Through Membrane Progesterone Receptors (PAQRs) in Neuronal Cells.
    Thomas P; Pang Y
    Front Endocrinol (Lausanne); 2020; 11():417. PubMed ID: 32670200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of behavioral effects of drugs in mice by neuroactive steroids.
    Ungard JT; Beekman M; Gasior M; Carter RB; Dijkstra D; Witkin JM
    Psychopharmacology (Berl); 2000 Mar; 148(4):336-43. PubMed ID: 10928304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.